DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.
- DOI
- 10.1016/j.esmogo.2026.100406
- Published
- 2026 Sep
- Container
- ESMO gastrointestinal oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmogo.2026.100406,
title = {DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.},
author = {Gordon A and Cartwright E and Tran A and Crux R and Turkes F and Smyth E and Smith A and Manalang I and Rana I and Kohoutova D and Johnston E and Dunlop A and Ul-Islam MS and Falk S and Sita-Lumsden A and Rao S and Starling N and Chau I and Cunningham D},
year = {2026},
journal = {ESMO gastrointestinal oncology},
doi = {10.1016/j.esmogo.2026.100406},
url = {https://doi.org/10.1016/j.esmogo.2026.100406}
}RIS
TY - JOUR TI - DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial. AU - Gordon A AU - Cartwright E AU - Tran A AU - Crux R AU - Turkes F AU - Smyth E AU - Smith A AU - Manalang I AU - Rana I AU - Kohoutova D AU - Johnston E AU - Dunlop A AU - Ul-Islam MS AU - Falk S AU - Sita-Lumsden A AU - Rao S AU - Starling N AU - Chau I AU - Cunningham D PY - 2026 JO - ESMO gastrointestinal oncology DO - 10.1016/j.esmogo.2026.100406 UR - https://doi.org/10.1016/j.esmogo.2026.100406 ER -
APA
A, G., E, C., A, T., R, C., F, T., E, S., A, S., I, M., I, R., D, K., E, J., A, D., MS, U., S, F., A, S., S, R., N, S., I, C., & D, C. (2026). DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100406